These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 3361655)

  • 21. Effects of drinking water quality on urinary parameters in men with and without urinary tract stones.
    Mirzazadeh M; Nouran MG; Richards KA; Zare M
    Urology; 2012 Mar; 79(3):501-7. PubMed ID: 22173182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High fluid intake or pharmacological therapy in recurrent stone former patients?
    Aroldi A; Graziani G; Passerini P; Castelnovo C; Mandressi A; Trinchieri A; Colussi G; Ponticelli C
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():743-6. PubMed ID: 3991571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in urine volume accomplished by physicians treating nephrolithiasis.
    Parks JH; Goldfischer ER; Coe FL
    J Urol; 2003 Mar; 169(3):863-6. PubMed ID: 12576800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers.
    Kumar V; Peña de la Vega L; Farell G; Lieske JC
    Kidney Int; 2005 Oct; 68(4):1784-92. PubMed ID: 16164655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Idiopathic hypercalciuria].
    Tsujimura H; Hiraishi K
    Nihon Hinyokika Gakkai Zasshi; 1983 Mar; 74(3):368-78. PubMed ID: 6632446
    [No Abstract]   [Full Text] [Related]  

  • 26. Urinary ionic calcium and binding sites in normocalciuric idiopathic calcium urolithiasis.
    Jacobson AL; Singhal PC; Mandin H; Hyne JB
    Invest Urol; 1979 Nov; 17(3):218-22. PubMed ID: 500320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear magnetic resonance study of an ethyl cellulose sustained-release delivery system. I: Effect of casting solvent on hydration properties.
    Azoury R; Elkayam R; Friedman M
    J Pharm Sci; 1988 May; 77(5):425-7. PubMed ID: 3411466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Is it necessary to systematically reduce dietary calcium intake in lithiasic patients?].
    Fuss M; Van Geel J; Pepersack T; Bergmann P; Van de Walle JC; Simon J
    Acta Urol Belg; 1988; 56(4):511-5. PubMed ID: 3207083
    [No Abstract]   [Full Text] [Related]  

  • 29. A new approach to the study of urinary macromolecules as a participant in calcium oxalate crystallization.
    Morse RM; Resnick MI
    J Urol; 1988 Apr; 139(4):869-73. PubMed ID: 3352063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers.
    Borghi L; Guerra A; Meschi T; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Mar; 55(3):1041-50. PubMed ID: 10027942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ascorbic acid consumption on urinary stone risk factors.
    Traxer O; Huet B; Poindexter J; Pak CY; Pearle MS
    J Urol; 2003 Aug; 170(2 Pt 1):397-401. PubMed ID: 12853784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones.
    Gault MH; Chafe LL; Morgan JM; Parfrey PS; Harnett JD; Walsh EA; Prabhakaran VM; Dow D; Colpitts A
    Medicine (Baltimore); 1991 Nov; 70(6):345-59. PubMed ID: 1956278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The most important metabolic risk factors in recurrent urinary stone formers.
    Parvin M; Shakhssalim N; Basiri A; Miladipour AH; Golestan B; Mohammadi Torbati P; Azadvari M; Eftekhari S
    Urol J; 2011; 8(2):99-106. PubMed ID: 21656467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium restriction, thiazide, citrate, and allopurinol in calcium oxalate nephrolithiasis.
    Coe FL
    Acta Urol Belg; 1994 Jun; 62(2):25-9. PubMed ID: 8037000
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of calcium oxalate kidney stones with thiazides].
    Alon U; Better OS
    Harefuah; 1982 Apr; 102(8):338-40. PubMed ID: 7117975
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapeutic measures in recurrent calcium oxalate nephrolithiasis].
    Tschöpe W; Schmidt-Gayk H; Ritz E
    Schweiz Rundsch Med Prax; 1978 Sep; 67(38):1385-8. PubMed ID: 211499
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of urinary organic macromolecules on crystallization of calcium oxalate: enhancement of nucleation.
    Drach GW; Thorson S; Randolph A
    J Urol; 1980 Apr; 123(4):519-23. PubMed ID: 7365890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of calcium nephrolithiasis with potassium citrate.
    Pak CY; Fuller C; Sakhaee K; Preminger GM; Britton F
    J Urol; 1985 Jul; 134(1):11-9. PubMed ID: 3892044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Calcium oxalate activity products and discriminant analysis of urinary parameters as basis for a calcium oxalate screening program (author's transl)].
    Brundig P; Berg W; Naumann J; Hoppe H; Cumme GA; Achilles W; Schneider HJ
    Urologe A; 1980 Jan; 19(1):54-6. PubMed ID: 7355530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.